Trinity biotech unveils cgm+: an ai-native platform targeting the $260 billion ai wearable market

Wilsonville, ore. and dublin, july 24, 2025 (globe newswire) -- trinity biotech plc (nasdaq: trib), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today unveiled its new flagship product, cgm+, a next-generation wearable biosensor platform designed for the $260 billion ai wearables market. now in the later stages of device development, cgm+ is trinity's new ai-native continuous glucose monitoring (cgm) system, combining multi-sensor data and real-time analytics to meet the evolving demands of ai-powered healthcare and wellness.
TRIB Ratings Summary
TRIB Quant Ranking